SCHEMBL5133732

SCHEMBL5133732

Cc1ccc(Nc2cc(OC3CCCCN3C(=O)OC(C)(C)C)ncn2)c(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.41
EPHA2 P29317 1/20 0.37
KDR P35968 1/20 0.37
EPHB4 P54760 1/20 0.37
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD11B1 P28845 1/20 0.36
FLT3 P36888 3/20 0.36
CDK2 P24941 1/20 0.36
CDK6 Q00534 1/20 0.36
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36
PRKDC P78527 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
ALK Q9UM73 2/20 0.35
TBK1 Q9UHD2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391509 0.85 GPR119 (0.54) GPR119TBK1
SCHEMBL5188837 0.81 GPR119 (0.40) GPR119LMNANPSR1MEN1KMT2A
SCHEMBL4719749 0.79 GPR119 (0.45) GPR119FLT3CDK2CDK6TBK1
SCHEMBL388449 0.75 GPR119 (0.70) GPR119
SCHEMBL13685341 0.75 GPR119 (0.53) GPR119EPHB4FLT3CDK2CDK6
SCHEMBL391661 0.73 GPR119 (0.60) GPR119TBK1
SCHEMBL4723041 0.71 GPR119 (0.55) GPR119FLT3CDK2CDK6
SCHEMBL390253 0.70 GPR119 (0.60) GPR119PIK3CAMTORPRKDCTBK1
SCHEMBL390190 0.70 GPR119 (0.60) GPR119
SCHEMBL29986931 0.69 ALDH1A1 (0.38) GPR119LMNANPSR1HSD11B1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed